OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Chromatography Online. All rights reserved.
Special Issues
FDA is modernizing and streamlining the regulatory processes for product development. This article examines FDA's proposed rule to exempt the production of Phase 1 clinical trial materials from the GMP regulations and questions whether this proposed exemption will truly improve public health and promote faster and more predictable access to new medicines.